

AlphaVax Names Jonathan Smith Chief Scientific Officer

Research Triangle Park, N.C. – AlphaVax has promoted Jonathan Smith, Ph.D., to the position of chief scientific officer. Smith is one of the original scientific founders of AlphaVax and has served as senior vice president, discovery, since 2000. He will now be responsible for discovery, research and development.

AlphaVax is developing a new vaccine technology with broad potential applications in infectious diseases and cancer. The company's first human clinical trials were initiated earlier this year. AlphaVax has also received multiple grants from the National Institutes of Health.

"Jonathan is one of the pre-eminent world experts in the type of vaccine technology we are using," said Peter Young, AlphaVax president and CEO. "This promotion reflects the impact he has had on the technology since joining AlphaVax, as well as our ongoing need to grow and develop an integrated R&D organization and capability. Jonathan has made a literally transforming contribution over the last three years, and his new role expands his ability to continue doing so."

Before joining AlphaVax, Smith was one of the leading scientists and vaccinologists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), where he served as chief of the Department of Viral Biology. He has been a leader in developing genetically engineered, live attenuated vaccines for several viruses, as well as generating new vaccine vectors based on the AlphaVax ArV™ technology. Dr. Smith graduated from Colby College and earned his Ph.D. in Microbiology and Virology from the University of Texas at Austin. He completed postdoctoral training at the Institute of Genetics in Cologne, Germany.